Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.

Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.

Utrophin is highly homologous and structurally similar to dystrophin, and in gene delivery experiments in mdx mice was able to functionally replace dystrophin. We performed mini-utrophin gene transfer in Golden Retriever dogs with canine muscular dystrophy (CXMD). Unlike the mouse model, the clinico...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Cerletti, M, Negri, T, Cozzi, F, Colpo, R, Andreetta, F, Croci, D, Davies, K, Cornelio, F, Pozza, O, Karpati, G, Gilbert, R, Mora, M
Natura:	Journal article
Lingua:	English
Pubblicazione:	2003

Documenti analoghi

Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.
di: Wakefield, P, et al.
Pubblicazione: (2000)

Utrophin upregulation in Duchenne muscular dystrophy.
di: Hirst, R, et al.
Pubblicazione: (2005)

Utrophin in the therapy of Duchenne Muscular Dystrophy
di: Potter, A, et al.
Pubblicazione: (2006)

The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
di: Perkins, K, et al.
Pubblicazione: (2002)

Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.
di: Chancellor, DR, et al.
Pubblicazione: (2011)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
di: Guiraud, S, et al.
Pubblicazione: (2019)

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy
di: Fairclough, R, et al.
Pubblicazione: (2012)

Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy
di: Wilkinson, I
Pubblicazione: (2019)

Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy.
di: Griffin, J, et al.
Pubblicazione: (2002)

Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy
di: Ruo Wu, et al.
Pubblicazione: (2022-11-01)

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy
di: Fairclough, R, et al.
Pubblicazione: (2008)

Utrophin in therapy of Duchenne muscular distrophy
di: Fisher, R
Pubblicazione: (2001)

Utrophin upregulation and microRNAs - two avenues of Duchenne muscular dystrophy therapy research
di: Bareja, A
Pubblicazione: (2011)

Expression of different isoforms of utrophin in human muscle; potentials for therapy of Duchenne muscular dystrophy
di: Sewry, C, et al.
Pubblicazione: (2004)

Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
di: Kennedy, T, et al.
Pubblicazione: (2017)

Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
di: Tahnee L. Kennedy, et al.
Pubblicazione: (2017-10-01)

New orally available compounds which modulate utrophin expression for the therapy of Duchenne muscular dystrophy (DMD)
di: Fairclough, R, et al.
Pubblicazione: (2014)

Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies
di: Janghra, N, et al.
Pubblicazione: (2016)

Analysis of the transcriptional control of utrophin promoters as a therapeutic strategy for Duchenne muscular dystrophy (DMD).
di: Perkins, K, et al.
Pubblicazione: (2000)

Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression
di: Angelina M. Georgieva, et al.
Pubblicazione: (2022-07-01)

Up-regulation of utrophin alleviates the dystrophic phenotype in the mdx mouse heart
di: Sang, E, et al.
Pubblicazione: (2000)

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
di: Tinsley, J, et al.
Pubblicazione: (2013)

Metabolic dysfunction and altered mitochondrial dynamics in the utrophin-dystrophin deficient mouse model of duchenne muscular dystrophy.
di: Meghna Pant, et al.
Pubblicazione: (2015-01-01)

Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction.
di: Manoj K Mishra, et al.
Pubblicazione: (2017-01-01)

Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy
di: Perkins, K, et al.
Pubblicazione: (2018)

Differential requirement for utrophin in the induced pluripotent stem cell correction of muscle versus fat in muscular dystrophy mice.
di: Amanda J Beck, et al.
Pubblicazione: (2011-01-01)

Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice
di: Emily Freeman, et al.
Pubblicazione: (2024-04-01)

Abnormal carbohydrate metabolism in a canine model for muscular dystrophy
di: Andressa R. Amaral, et al.
Pubblicazione: (2017-01-01)

Metabolic remodeling of dystrophic skeletal muscle reveals biological roles for dystrophin and utrophin in adaptation and plasticity
di: Justin P. Hardee, et al.
Pubblicazione: (2021-03-01)

Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
di: Narinder Janghra, et al.
Pubblicazione: (2016-01-01)

Macroglossia and less advanced dystrophic change in the tongue muscle of the Duchenne muscular dystrophy rat
di: Keitaro Yamanouchi, et al.
Pubblicazione: (2022-10-01)

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
di: Tinsley, J, et al.
Pubblicazione: (2011)

Glycine administration attenuates progression of dystrophic pathology in prednisolone-treated dystrophin/utrophin null mice
di: Daniel J. Ham, et al.
Pubblicazione: (2019-09-01)

The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy.
di: Perkins, K, et al.
Pubblicazione: (2001)

Nitric Oxide and l-Arginine Cause an Accumulation of Utrophin at the Sarcolemma: A Possible Compensation for Dystrophin Loss in Duchenne Muscular Dystrophy
di: Emmanuel Chaubourt, et al.
Pubblicazione: (1999-12-01)

Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy
di: Francesca M. Alves, et al.
Pubblicazione: (2022-06-01)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
di: Goyenvalle, A, et al.
Pubblicazione: (2010)

Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.
di: Antoine Boulanger Piette, et al.
Pubblicazione: (2018-01-01)

Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy
di: Guttridge Denis C, et al.
Pubblicazione: (2011-05-01)

Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles
di: Christine Péladeau, et al.
Pubblicazione: (2020-04-01)